



Galgo Medical receives FDA 510(k) Clearance of its software ADAS 3D

Barcelona, Feb. 18, 2020 – Galgo Medical announces US. Food and Drug Administration (FDA) 510(k) clearance of the software ADAS 3D that helps cardiologists, electrophysiologist, radiologists and technicians to visualize fibrosis, wall thickness and surrounding anatomical structures of the heart. The software is indicated for the use in the clinical setting to support the visualization and analysis of cardiac MR and CTA images for patients with cardiovascular disease.

“Galgo Medical established itself as an early innovator in this field and through the partnership with Circle we're looking forward to continue to make ADAS 3D globally available to the electrophysiology community and now also extensively in the USA”, commented Luis Serra, President of ADAS3D Medical.

ADAS 3D is a software-based image processing tool for post-processing cardiovascular enhanced Magnetic Resonance (MRI) images and Computed Tomography Angiography (CTA) images. And it is designed to process DICOM images databases to enable the calculation, quantification and visualization of 3D cardiac imaging data by displaying and quantifying the levels of enhancement.

ADAS 3D also enables the visualization of the shape of the cardiac chamber and the adjacent anatomy. After data processing, the data and images can be exported utilizing industry standard formats for viewing on other system, including Electrophysiology (EP) navigation system.

For more information, please contact us at info@adas3d.com or visit our website at [ADAS3D](http://ADAS3D.com).

ABOUT GALGO MEDICAL

Galgo Medical SL is a Barcelona-based company focused on expanding the use of Cardiac Imaging (MRI and CT) to electrophysiologists. Galgo established itself as an early imaging innovator by partnering with EPs to introduce the ADAS 3D software which is intended to help with the identification of fibrotic substrate that may be critical to the differential diagnosis and pre-procedure treatment planning.

ABOUT ADAS3D MEDICAL

ADAS3D Medical is the recent offspring of the electrophysiology business of Galgo Medical SL (Barcelona, Spain) in partnership with Circle Cardiovascular Imaging Inc. (Calgary, Canada). Its

mission is to expand accessibility and use of Cardiac Imaging (MRI and CT) to electrophysiology procedures such as Atrial Fibrillation and Ventricular Tachycardia ablations. ADAS3D established itself as an early innovator in this field by introducing software intended for the identification of arrhythmia substrate and guidance of ablation treatment, for safer and more efficient procedures.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.